18:53 , Aug 10, 2018 |  BC Week In Review  |  Clinical News

Theravance's TD-9855 improves symptom severity in Phase II for hypotension

Theravance Biopharma Inc. (NASDAQ:TBPH) reported data from 16 patients with symptomatic neurogenic orthostatic hypotension in Part C of a Phase II trial showing that once-daily TD-9855 led to a mean symptom improvement of 2.4 points...
07:00 , May 5, 2014 |  BC Week In Review  |  Clinical News

TD-9855: Phase II data

A double-blind, U.S. Phase II trial in 392 patients with fibromyalgia showed that once-daily 20 mg TD-9855 met the primary endpoint of reducing the average of daily pain score from baseline during the last week...
07:00 , May 5, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Acorda Therapeutics Inc. (NASDAQ:ACOR) fell $3.51 (10%) to $32.39 on Friday after FDA asked for an additional clinical trial in a complete response letter for Plumiaz diazepam nasal spray to treat acute repetitive...
00:43 , May 1, 2014 |  BC Extra  |  Clinical News

Theravance reports Phase II fibromyalgia data

Theravance Inc. (NASDAQ:THRX) reported results late Wednesday from a 392-patient Phase II trial evaluating once-daily TD-9855 to treat fibromyalgia. Once-daily 20 mg TD-9855 met the primary endpoint of reducing from baseline the average daily pain...
07:00 , Apr 7, 2014 |  BioCentury  |  Regulation

Confirming endpoints

Testimony from patients at an FDA workshop on fibromyalgia suggests drug developers aiming to reduce pain are on the right track, because many patients said existing drugs do not provide adequate relief. Discussion at the...
08:00 , Dec 16, 2013 |  BC Week In Review  |  Clinical News

TD-9855: Development discontinued

Theravance disclosed in a November SEC filing that the company will discontinue development of TD-9855 to treat ADHD after data from a double-blind, U.S. Phase II trial showed the compound missed the primary endpoint of...
07:00 , Apr 29, 2013 |  BC Week In Review  |  Company News

Theravance infectious, gastrointestinal, pulmonary news

Theravance plans to split into two publicly traded companies to separate its partnered late-stage respiratory assets from its R&D. One company - Royalty Management Co. - will manage all development and commercial responsibilities, plus potential...
01:04 , Apr 26, 2013 |  BC Extra  |  Company News

Theravance splitting up

Theravance Inc. (NASDAQ:THRX) announced plans late Thursday to split into two publicly traded companies to separate its late-stage, partnered respiratory assets from its R&D. One company -- Royalty Management Co. -- will manage all development...
08:00 , Dec 10, 2012 |  BC Week In Review  |  Clinical News

TD-9855: Phase II started

Theravance began a placebo-controlled, double-blind, U.S. Phase II trial to evaluate 2 doses of once-daily TD-9855 for up to 9 weeks in about 375 patients. Theravance Inc. (NASDAQ:THRX), South San Francisco, Calif.   Product: TD-9855...
08:00 , Dec 19, 2011 |  BC Week In Review  |  Clinical News

TD-9855: Phase II started

Theravance began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 2 doses of oral TD-9855 daily for 6 weeks in about 285 adult male ADHD patients. Theravance Inc. (NASDAQ:THRX), South San Francisco, Calif.  ...